Discovering The Potential Applications of PDE11A as A Drug Target Or Biomarker

Target Name: PDE11A

NCBI ID: G50940

PDE11A

Other Name(s): Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (isoform 3) | PDE11A variant 1 | Cyclic nucleotide phosphodiesterase 11A4 | FLJ23693 | Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (isofor

Discovering The Potential Applications of PDE11A as A Drug Target Or Biomarker

PDE11A (Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A) is a protein that is expressed in various tissues and cells in the human body. It is a key enzyme in the AMP/GMP signaling pathway, which is involved in a wide range of physiological processes, including cell signaling, neurotransmission, and hormone regulation. In this article, we will discuss the potential implications of PDE11A as a drug target or biomarker.

PDE11A Structure and Function

PDE11A is a member of the family of cGMP-dependent phosphatase (PDE) enzymes, which are involved in the regulation of second messenger gases, including cAMP and cGMP. These enzymes catalyze the phosphorification of the second messenger acids, which results in the formation of inactive 5'-phosphates. PDE11A is characterized by its dual catalytic activity, with both 3',5'-cyclic-AMP and -GMP phosphodiesterase activities.

The 3',5'-cyclic-AMP phosphodiesterase activity of PDE11A is critical for the regulation of the intracellular signaling pathway, which is involved in a wide range of cellular processes, including cell growth, differentiation, and apoptosis. '-cyclic-AMP phosphodiesterase activity of PDE11A is responsible for the breakdown of cAMP, which is a key second messenger acid that plays a vital role in intracellular signaling. The breakdown of cAMP by PDE11A allows for the formation of inactive 5'-phosphates, which are then removed by other enzymes, such as the protein phosphatidylinositol (PI) synthase.

The -GMP phosphodiesterase activity of PDE11A is involved in the regulation of neurotransmission, including the transmission of signals from the brain to the rest of the body. The -GMP phosphodiesterase activity of PDE11A is responsible for the breakdown of -GMP, which is a key second messenger acid that is involved in neurotransmission. The breakdown of -GMP by PDE11A allows for the formation of active -GMP, which can then interact with other signaling molecules, such as the neurotransmitter acetylcholine.

PDE11A Interactions with Other Proteins

PDE11A is a component of several signaling pathways that are involved in various cellular processes. One of the well-known signaling pathways that is regulated by PDE11A is the PI signaling pathway. PDE11A is involved in the breakdown of PI, which is a key second messenger acid that is involved in intracellular signaling. The breakdown of PI by PDE11A allows for the formation of inactive 5'-phosphates, which are then removed by other enzymes, such as the protein kinase CK2.

PDE11A is also involved in the regulation of the FGF signaling pathway, which is involved in cell signaling and tissue regeneration. The FGF signaling pathway is regulated by the protein FGF-1, which is a potent growth factor that plays a vital role in the development and maintenance of tissues. PDE11A is involved in the breakdown of FGF-1, which allows for the formation of inactive 5'-phosphates.

PDE11A is also involved in the regulation of the PIP3 signaling pathway, which is involved in cell signaling and neurotransmission. The PIP3 signaling pathway is regulated by the protein

Protein Name: Phosphodiesterase 11A

Functions: Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP (PubMed:10725373, PubMed:10906126, PubMed:11050148, PubMed:16330539). Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively (PubMed:10725373, PubMed:10906126, PubMed:11050148)

The "PDE11A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE11A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets